HSS Journal

, Volume 2, Issue 1, pp 30–41 | Cite as

Combination Therapy for Rheumatoid Arthritis in the Era of Biologicals

  • Allan Gibofsky
Original Article


Early, aggressive disease management is critical for halting disease progression and joint destruction in patients with rheumatoid arthritis. Combination therapy with at least two disease-modifying antirheumatic drugs, such as methotrexate (MTX), sulfasalazine, or hydroxychloroquine, is often more effective than monotherapy in reducing disease activity. Biologic therapies represent more effective and tolerable treatment options that, when combined with MTX, have been shown to dramatically reduce inflammation, inhibit radiographic progression, and induce remission. Although several types of treatment strategies are used in clinical practice, the most aggressive approaches that target early disease have shown the most promise in reversing disease progression and reducing disease-related costs.

Key words

combination therapy disease-modifying antirheumatic drugs joint destruction rheumatoid arthritis tumor necrosis factor antagonists 



The thoughtful suggestions of Dr. C. Ronald MacKenzie and Dr. Sergio Schwartzman are gratefully appreciated. I thank Ting Chang and Ruth Pereira for editorial support.


  1. 1.
    Gabriel, SE 2001The epidemiology of rheumatoid arthritisRheum Dis Clin North Am27269281CrossRefPubMedGoogle Scholar
  2. 2.
    Lee, DM, Weinblatt, ME 2001Rheumatoid arthritisLancet358903911CrossRefPubMedGoogle Scholar
  3. 3.
    McQueen, FM, Stewart, N, Crabbe, J,  et al. 1998Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onsetAnn Rheum Dis57350356PubMedGoogle Scholar
  4. 4.
    Fuchs, HA, Kaye, JJ, Callahan, LF,  et al. 1989Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of diseaseJ Rheumatol16585591PubMedGoogle Scholar
  5. 5.
    Felts, W, Yelin, E 1989The economic impact of the rheumatic diseases in the United StatesJ Rheumatol16867884PubMedGoogle Scholar
  6. 6.
    Weinblatt, ME 2004Rheumatoid arthritis: more aggressive approach improves outlookClevel Clin J Med71409413Google Scholar
  7. 7.
    Heijde, DM 1995Joint erosions and patients with early rheumatoid arthritisBr J Rheumatol347478PubMedGoogle Scholar
  8. 8.
    Heijde, DM, Leeuwen, MA, Riel, PL,  et al. 1995Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)J Rheumatol2217921796PubMedGoogle Scholar
  9. 9.
    Stenger, AA, Leeuwen, MA, Houtman, PM,  et al. 1998Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progressionBr J Rheumatol3711571163CrossRefPubMedGoogle Scholar
  10. 10.
    Lard, LR, Visser, H, Speyer, I,  et al. 2001Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategiesAm J Med111446451CrossRefPubMedGoogle Scholar
  11. 11.
    Boers, M, Verhoeven, AC, Markusse, HM,  et al. 1997Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisLancet350309318CrossRefPubMedGoogle Scholar
  12. 12.
    Korpela, M, Laasonen, L, Hannonen, P,  et al. 2004Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo studyArthritis Rheum5020722081CrossRefPubMedGoogle Scholar
  13. 13.
    Kremer, JM, Genovese, MC, Cannon, GW,  et al. 2002Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialAnn Intern Med137726733PubMedGoogle Scholar
  14. 14.
    Landewe, RB, Boers, M, Verhoeven, AC,  et al. 2002COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief interventionArthritis Rheum46347356PubMedGoogle Scholar
  15. 15.
    O'Dell, JR, Haire, CE, Erikson, N,  et al. 1996Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medicationsN Engl J Med33412871291CrossRefPubMedGoogle Scholar
  16. 16.
    O'Dell, JR, Leff, R, Paulsen, G,  et al. 2002Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trialArthritis Rheum4611641170PubMedGoogle Scholar
  17. 17.
    Tugwell, P, Pincus, T, Yocum, D,  et al. 1995Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate–Cyclosporine Combination Study GroupN Engl J Med333137141CrossRefPubMedGoogle Scholar
  18. 18.
    Dougados, M, Combe, B, Cantagrel, A,  et al. 1999Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single componentsAnn Rheum Dis58220225PubMedCrossRefGoogle Scholar
  19. 19.
    Haagsma, CJ, Riel, PL, Jong, AJ,  et al. 1997Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trialBr J Rheumatol3610821088CrossRefPubMedGoogle Scholar
  20. 20.
    Proudman, SM, Conaghan, PG, Richardson, C,  et al. 2000Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine aloneArthritis Rheum4318091819CrossRefPubMedGoogle Scholar
  21. 21.
    Borne, BE, Landewe, RB, Goei The, HS,  et al. 1998Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquineJ Rheumatol2514931498PubMedGoogle Scholar
  22. 22.
    Enbrel® (etanercept) [package insert] (2004) Thousand Oaks, CA: Amgen Inc. and Wyeth-Ayerst PharmaceuticalsGoogle Scholar
  23. 23.
    Remicade® (infliximab) [package insert] (2003) Malvern, PA: Centacor Inc.Google Scholar
  24. 24.
    Humira® (adalimumab) [package insert] (2003) North Chicago, IL: Abbott LaboratoriesGoogle Scholar
  25. 25.
    Kineret® (anakinra) [package insert] (2002) Thousand Oaks, CA; Amgen Inc.Google Scholar
  26. 26.
    Cohen, S, Hurd, E, Cush, J,  et al. 2002Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum46614624PubMedGoogle Scholar
  27. 27.
    Furst, DE, Schiff, MH, Fleischmann, RM,  et al. 2003Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)J Rheumatol3025632571PubMedGoogle Scholar
  28. 28.
    Klareskog, L, Heijde, D, Jager, JP,  et al. 2004Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet363675681PubMedGoogle Scholar
  29. 29.
    Maini, R, St Clair, EW, Breedveld, F,  et al. 1999Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, ATTRACT Study GroupLancet35419321939CrossRefPubMedGoogle Scholar
  30. 30.
    Maini, RN, Breedveld, FC, Kalden, JR,  et al. 2004Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexateArthritis Rheum5010511065CrossRefPubMedGoogle Scholar
  31. 31.
    Weinblatt, ME, Keystone, EC, Furst, DE,  et al. 2003Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialArthritis Rheum483545CrossRefPubMedGoogle Scholar
  32. 32.
    Weinblatt, ME, Kremer, JM, Bankhurst, AD,  et al. 1999A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med340253259CrossRefPubMedGoogle Scholar
  33. 33.
    Pinals, RS, Masi, AT, Larsen, RA 1981Preliminary criteria for clinical remission in rheumatoid arthritisArthritis Rheum2413081315PubMedGoogle Scholar
  34. 34.
    Prevoo, ML, Gestel, AM, T'Hof, MA,  et al. 1996Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity scoreBr J Rheumatol3511011105CrossRefPubMedGoogle Scholar
  35. 35.
    Klareskog L, van der Heijde D, de Jager JP et al (2004) Clinical outcomes of a double-blind study of etanercept and methotrexate, alone and combined, in patients with active rheumatoid arthritis (TEMPO trial), year 2 results [Abstract]. Ann Rheum Dis 63Google Scholar
  36. 36.
    van der Heijde D, Klareskog L, Pedersen R et al (2004) Assessment of functional status among patients with active rheumatoid arthritis in a double-blind trial of etanercept and methotrexate, alone and combined (TEMPO trial) [Abstract]. Arthritis Rheum 50Google Scholar
  37. 37.
    Heijde, D, Landewe, R, Klareskog, L,  et al. 2005Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO studyArthritis Rheum524960CrossRefPubMedGoogle Scholar
  38. 38.
    Baumgartner, SW, Fleischmann, RM, Moreland, LW,  et al. 2004Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disabilityJ Rheumatol3115321537PubMedGoogle Scholar
  39. 39.
    St Clair, EW, Heijde, DM, Smolen, JS,  et al. 2004Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trialArthritis Rheum5034323443PubMedGoogle Scholar
  40. 40.
    Smolen J, van der Heijde DM, Emery P et al (2003) Methotrexate naive early rheumatoid arthritis (RA) patients with higher baseline ESR and CRP derive greater radiographic benefit from initiating treatment with a combination of infliximab and methotrexate [Abstract]. Arthritis Rheum 48Google Scholar
  41. 41.
    Breedveld, FC, Emery, P, Keystone, E,  et al. 2004Infliximab in active early rheumatoid arthritisAnn Rheum Dis63149155PubMedGoogle Scholar
  42. 42.
    Breedveld FC, Kavanaugh AF, Cohen SB et al (2004) Early treatment of rheumatoid arthritis (RA) with adalimumab (Humira) plus methotrexate vs. adalimumab alone or methotrexate alone: the PREMIER study [Abstract]. Arthritis Rheum 50Google Scholar
  43. 43.
    Keystone, EC, Haraoui, B, Bykerk, VP 2003Role of adalimumab in the treatment of early rheumatoid arthritisClin Exp Rheumatol21S198S199PubMedGoogle Scholar
  44. 44.
    Keystone EC, Kavanaugh A, Sharp J et al (2002) Adalimumab (D2E7), a fully human anti-TNF monoclonal antibody inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [Abstract]. Arthritis Rheum 46Google Scholar
  45. 45.
    Keystone, EC, Kavanaugh, AF, Sharp, JT,  et al. 2004Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialArthritis Rheum5014001411PubMedGoogle Scholar
  46. 46.
    Cohen, SB, Moreland, LW, Cush, JJ,  et al. 2004A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexateAnn Rheum Dis6310621068PubMedGoogle Scholar
  47. 47.
    Fries, JF 1999Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritisAnn Rheum Dis58I86I89PubMedGoogle Scholar
  48. 48.
    Mullan, RH, Bresnihan, B 2003Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritisClin Exp Rheumatol21S158S164PubMedGoogle Scholar
  49. 49.
    Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Zeben DV et al (2004) Treatment strategies in early rheumatoid arthritis: clinical and radiologic outcomes after 2 year follow-up of the BeST Study [Abstract]. Arthritis Rheum 50Google Scholar
  50. 50.
    Grigor, C, Capell, H, Stirling, A,  et al. 2004Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialLancet364263269CrossRefPubMedGoogle Scholar
  51. 51.
    Aletaha, D, Smolen, JS 2002Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational studyJ Rheumatol2916311638PubMedGoogle Scholar
  52. 52.
    Cannella, AC, O'Dell, JR 2003Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?Curr Opin Rheumatol15185192CrossRefPubMedGoogle Scholar
  53. 53.
    Mottonen, T, Hannonen, P, Leirisalo-Repo, M,  et al. 1999Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial, FIN-RACo trial groupLancet35315681573CrossRefPubMedGoogle Scholar
  54. 54.
    Wolfe F, Michaud K (2004) Prednisone but not biologics or DMARDs is associated with increased risk of myocardial infarction in persons with RA [Abstract]. Ann Rheum Dis 63Google Scholar
  55. 55.
    Wolfe F, Michaud K (2004) Rates and risk factors for herpes zoster in patients with rheumatoid arthritis [Abstract]. Ann Rheum Dis 63Google Scholar
  56. 56.
    Wolfe F, Michaud K (2004) Corticosteroids increase the risk of diabetes mellitus in RA and contribute to the risk of myocardial infarction and heart failure [Abstract]. Ann Rheum Dis 63Google Scholar
  57. 57.
    Everdingen, AA, Siewertsz van Reesema, DR, Jacobs, JW,  et al. 2003Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?Clin Exp Rheumatol21155160PubMedGoogle Scholar
  58. 58.
    Genovese MC, Martin RW, Fleischmann RM et al (2003) Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA trial): clinical and radiographic data [Abstract]. Arthritis Rheum 47(Suppl)Google Scholar
  59. 59.
    Singh A, Van der Heijde D, Klareskog L et al (2004) Assessment of treatment satisfaction among patients with active rheumatoid arthritis in a double-blind trial of etanercept and methotrexate, alone and combined (TEMPO trial) [Abstract]. Arthritis Rheum 50(Suppl)Google Scholar
  60. 60.
    Maillefert, JF, Combe, B, Goupille, P,  et al. 2003Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled studyAnn Rheum Dis62764766PubMedGoogle Scholar
  61. 61.
    Genovese, MC, Cohen, S, Moreland, L,  et al. 2004Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis Rheum5014121419CrossRefPubMedGoogle Scholar
  62. 62.
    Wilske, KR, Healey, LA 1989Remodeling the pyramid—a concept whose time has comeJ Rheumatol16565567PubMedGoogle Scholar
  63. 63.
    Kremer, JM, Weinblatt, ME, Bankhurst, AD,  et al. 2003Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observationsArthritis Rheum4814931499PubMedGoogle Scholar
  64. 64.
    Fries, JF 1990Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategyJ Rheumatol, Suppl221215Google Scholar
  65. 65.
    Sokka, TM, Kaarela, K, Mottonen, TT,  et al. 1999Conventional monotherapy compared to a “sawtooth” treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight yearsClin Exp Rheumatol17527532PubMedGoogle Scholar
  66. 66.
    Mottonen, T, Paimela, L, Ahonen, J,  et al. 1996Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategyArthritis Rheum399961005PubMedGoogle Scholar
  67. 67.
    De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Van Zeben D et al (2004) A comparison of clinical and radiologic outcomes of four treatment strategies for early rheumatoid arthritis: results of the BEST trial [Abstract]. Ann Rheum Dis 63Google Scholar
  68. 68.
    De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Kerstens PJSM et al (2004) Patient preferences for treatment of newly diagnosed rheumatoid arthritis [Abstract]. Ann Rheum Dis 63Google Scholar
  69. 69.
    Breedveld FC et al (June 8–11, 2005) Presented at: EULAR Annual Meeting; Vienna, Austria. Abstract OP0013Google Scholar

Copyright information

© Hospital for Special Surgery 2006

Authors and Affiliations

  1. 1.Departments of Medicine and Public HealthWeill Medical College of Cornell UniversityNew YorkUSA
  2. 2.Hospital for Special SurgeryNew YorkUSA

Personalised recommendations